



PROVIDING ANSWERS FOR CANCER PATIENTS

Press release

17 November, 2022

Curasight to present at SEB Healthcare Seminar 2022

Copenhagen, Denmark, 17 November 2022 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company at SEB Healthcare Seminar 2022, 21 November 2022.

The presentation will include an update on the momentum and business progress made by the company during 2022 and look ahead at the coming news flow for rest of the year. Management will give an overall update on the company's pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain and prostate cancer as well as Neuroendocrine and head & neck cancer.

The presentation will be webcasted live 13:05-13:35 (CET), Monday 21 November 2022.

For more information – please [click here](#)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.